← Back to Search

Platinum-based Chemotherapy

Triple Drug Combo for Breast Cancer

Phase 1 & 2
Waitlist Available
Led By Priyanka Sharma, MD
Research Sponsored by Priyanka Sharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Breast cancer that is either stage III disease not amenable to curative therapy or stage IV
Eastern Oncology Cooperative Group (ECOG) Performance status of ≥ 2
Must not have
Subject has a concurrent malignancy or malignancy within 3 years of study enrollment
Subject has known history of testing positive for HIV or AIDS
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial found a combination of 3 drugs effective at treating metastatic TNBC & BRCA-mutated breast cancer.

Who is the study for?
This trial is for adults with triple negative breast cancer or BRCA mutation-associated breast cancer that's locally recurrent or metastatic. They must have had prior chemotherapy, be in a stable condition if they've had brain metastasis treatment, and not be pregnant. Those with certain health conditions, recent surgeries, active infections, or severe allergies are excluded.
What is being tested?
The study tests a combination of cisplatin (a chemotherapy drug), romidepsin (an anticancer agent), and nivolumab (an immunotherapy) on patients with advanced breast cancer to see how well it works compared to existing treatments.
What are the potential side effects?
Potential side effects include immune-related reactions like inflammation in organs, infusion-related symptoms such as fever or chills, fatigue from the therapy drugs themselves, possible blood count changes leading to increased infection risk and other common chemotherapy-related issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My breast cancer is at an advanced stage and cannot be cured with surgery or radiation.
Select...
My daily activity is limited due to my health condition.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had cancer within the last 3 years or have another cancer now.
Select...
I have tested positive for HIV/AIDS.
Select...
My nerve damage does not severely affect my daily activities.
Select...
I have an ongoing infection that isn't under control.
Select...
I am currently on medication that affects the enzyme CYP3A.
Select...
I have untreated brain symptoms.
Select...
I still have side effects from previous treatments that haven't improved much.
Select...
I haven't had any cancer treatment in the last 14 days or within 5 half-lives of the treatment.
Select...
My liver disease is severe.
Select...
I have inflammatory breast cancer.
Select...
I have tested positive for hepatitis B or C.
Select...
I am currently taking warfarin or a similar blood thinner.
Select...
I have heart problems or a history of heart issues.
Select...
I haven't had major surgery in the last 2 weeks or still have major side effects from it.
Select...
I have been treated with specific drugs for my condition before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2018 Phase 1 & 2 trial • 51 Patients • NCT01456039
100%
Dysgeusia
100%
Leukopenia
100%
Thrombocytopenia
100%
Lymphopenia
100%
Neutropenia
100%
Nausea
100%
Vomiting
100%
Pyrexia
100%
Fatigue
100%
Decreased appetite
100%
Peripheral Sensory neuropathy
67%
Diarrhoea
67%
Anaemia
67%
Lip dry
67%
Haemoglobin decreased
67%
Weight decreased
67%
Blood phosphorus increased
67%
Hypotension
67%
Insomnia
33%
Alanine aminotransferase increased
33%
Hypokalaemia
33%
Hyperhidrosis
33%
Hypocalcaemia
33%
Cancer Pain
33%
Oedema peripheral
33%
Vitreous Floaters
33%
Akathisia
33%
Biliary colic
33%
Abdominal pain upper
33%
Dental caries
33%
Gastritis
33%
Hypothermia
33%
Influenza like illness
33%
Non-cardiac chest pain
33%
Hypermagnesaemia
33%
Hyperuricaemia
33%
Blood alkaline phosphatase increased
33%
Blood urea increased
33%
Somnolence
33%
Rash macular
33%
Hypoxia
33%
Arthralgia
33%
Back Pain
33%
Musculoskeletal stiffness
33%
Osteoarthritis
33%
Periarthritis
33%
Nasopharyngitis
33%
Influenza
33%
Upper respiratory tract infection
33%
Long QT syndrome
33%
Contusion
33%
Procedural Pain
33%
Phlebitis
33%
Pollakiuria
33%
Headache
33%
Hiccups
100%
80%
60%
40%
20%
0%
Study treatment Arm
Phase 1: Romidepsin 9mg/m^2
Phase 1: Romidepsin 14mg/m^2
Phase 2: Romidepsin 14mg/m^2
Total: Romidepsin 14mg/m^2

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Romidepsin Dose ExpansionExperimental Treatment3 Interventions
Romidepsin maximum tolerated dose (MTD) from Phase I IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle Nivolumab 360mg on day 1 of each 21 day cycle
Group II: Romidepsin (8mg/m2) + Cisplatin (75mg/m2)Experimental Treatment2 Interventions
Romidepsin 8mg/m2 IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
Group III: Romidepsin (12mg/m2) + Cisplatin (75mg/m2)Experimental Treatment2 Interventions
Romidepsin 12mg/m2 IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
Group IV: Romidepsin (10mg/m2) + Cisplatin (75mg/m2)Experimental Treatment2 Interventions
Romidepsin 10mg/m2 IV on days 2 \& 9 of each 21 day cycle Cisplatin 75mg/m2 IV on day 1 of each 21 day cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Romidepsin
2011
Completed Phase 2
~790
Cisplatin
2013
Completed Phase 3
~3120
Nivolumab
2015
Completed Phase 3
~4010

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,696 Previous Clinical Trials
4,099,020 Total Patients Enrolled
50 Trials studying Breast Cancer
8,196 Patients Enrolled for Breast Cancer
Priyanka SharmaLead Sponsor
3 Previous Clinical Trials
1,144 Total Patients Enrolled
1 Trials studying Breast Cancer
43 Patients Enrolled for Breast Cancer
Celgene CorporationIndustry Sponsor
445 Previous Clinical Trials
58,595 Total Patients Enrolled
15 Trials studying Breast Cancer
674 Patients Enrolled for Breast Cancer
Priyanka Sharma, MDPrincipal InvestigatorUniversity of Kansas Medical Center
7 Previous Clinical Trials
1,815 Total Patients Enrolled
4 Trials studying Breast Cancer
1,561 Patients Enrolled for Breast Cancer

Media Library

Cisplatin (Platinum-based Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT02393794 — Phase 1 & 2
Breast Cancer Research Study Groups: Romidepsin (10mg/m2) + Cisplatin (75mg/m2), Romidepsin Dose Expansion, Romidepsin (12mg/m2) + Cisplatin (75mg/m2), Romidepsin (8mg/m2) + Cisplatin (75mg/m2)
Breast Cancer Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT02393794 — Phase 1 & 2
Cisplatin (Platinum-based Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02393794 — Phase 1 & 2
~5 spots leftby Dec 2025